Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LISATA THERAPEUTICS, INC.
Report date May 18, 2017 · Filed May 22, 2017
Section 16 reporting ended · disclosed 2017-05-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,786 |
Reported balance
After 2017-05-18 transaction · row 1
1 source rowRow 1 · 2017-05-18 · Tax withholding · Disposed 8,842 · Balance 33,786 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2017 Filed May 22, 2017 20:27 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 8,842 | $5.13 | $45,359.46 |
DisclosureSEC source: 0001144204-17-028879 · v467613_4.xml · nonDerivative · entry 1 Preti Robert A · CIK 0001510186 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,786 Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 20:18 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 247 | $4.74 | $1,170.78 |
DisclosureSEC source: 0001144204-17-022653 · v465289_form4.xml · nonDerivative · entry 1 Preti Robert A · CIK 0001510186 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,628 F1 · balance_after: Includes 17,050 shares of unvested restricted stock. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 22:03 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 272 | $3.87 | $1,052.64 |
DisclosureSEC source: 0001144204-17-004358 · v457628_4.xml · nonDerivative · entry 1 Preti Robert A · CIK 0001510186 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,870 F1 · balance_after: Includes 17,518 shares of unvested restricted stock. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 22:48 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option · Derivative | 27,500 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001144204-17-001859 · v456763_4.xml · derivative · entry 3 Preti Robert A · CIK 0001510186 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2027-01-09 F3 · security: 25% of the shares underlying the stock options vest immediately on the grant date and the remaining 75% of the shares underlying the stock options will vest annually over the following three years. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 22:48 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 2,482 | $3.54 | $8,786.28 |
DisclosureSEC source: 0001144204-17-001859 · v456763_4.xml · nonDerivative · entry 2 Preti Robert A · CIK 0001510186 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,142 F2 · balance_after: Includes 17,993 shares of unvested restricted stock. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 22:48 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 18,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-001859 · v456763_4.xml · nonDerivative · entry 1 Preti Robert A · CIK 0001510186 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,624 F1 · shares: Represents 18,300 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan. 25% of the shares of restricted stock vest immediately on the grant date and the remaining 75% of the shares of restricted stock will vest annually over the following three years. F2 · balance_after: Includes 17,993 shares of unvested restricted stock. Read SEC document |
| October 25, 2016 Filed Nov 10, 2016 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 164 | $4.12 | $675.68 |
DisclosureSEC source: 0001144204-16-133278 · v452730_4.xml · nonDerivative · entry 1 Preti Robert A · CIK 0001510186 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,331 F1 · balance_after: Includes 4,268 shares of unvested restricted stock. Read SEC document |
| September 29, 2016 Filed Sep 30, 2016 20:32 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option · Derivative | 20,894 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0001144204-16-126314 · v449789_4.xml · derivative · entry 1 Preti Robert A · CIK 0001510186 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,894 Underlying: Common Stock · 20,894 shares Expires 2026-09-29 F1 · security: These stock options were granted upon the Company's Compensation Committee approval on September 29, 2016, in consideration of the unpaid portion of the reporting person's discretionary 2015 target bonus. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.